Making continuous processing a reality in the pharmaceutical industry
21st August 2013 | | Mark Gibson Associate Director, Drug Product Manufacture & Delivery for AstraZeneca and Marcel de Matas, Principal Scientist at AstraZeneca |WATCH FOR FREE
THIS WEBINAR WAS LIVE ON 21ST AUGUST 2013.
Mark Gibson is currently responsible for clinical trial manufacture at AstraZeneca R&D in the UK. He is a Pharmacist educated at the University of Bradford (BPharm) and University of Bath (PhD). His experience encompasses almost 30 years in the pharmaceutical industry in the development of NCEs and line extensions of a wide range of dosage forms at American Cyanamid (Lederle), Fisons Pharmaceutics, Astra and AstraZeneca.
Marcel de Matas is a Principal Scientist at AstraZeneca (AZ) where he is focussed on advancing science and technology to improve product development. His current role is centred on implementing the strategy for continuous processing for formulated products. He has previously held positions at Rhone-Poulenc Rorer with a short period at the University of Bradford.